Terms: = Kidney tumors AND BCL6, BCL5, 603, 604, ENSG00000113916, ZBTB27, P41182, LAZ3, BCL6A, ZNF51 AND Treatment
31 results:
1. Using Crowdfunding Campaigns to Examine Financial Toxicity and Logistical Burdens Facing Families of Children With Wilms Tumor.
Leraas H; Moya-Mendez M; Donohue V; Kawano B; Olson L; Sekar A; Robles J; Wagner L; Greenup R; Haines KL; Tracy E
J Surg Res; 2023 Nov; 291():640-645. PubMed ID: 37542779
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy.
Wu Z; Chen H; Chen Q; Ge S; Yu N; Campi R; Gómez Rivas J; Autorino R; Rouprêt M; Psutka SP; Mehrazin R; Porpiglia F; Bensalah K; Black PC; Mir MC; Minervini A; Djaladat H; Margulis V; Bertolo R; Caliò A; Carbonara U; Amparore D; Borregales LD; Ciccarese C; Diana P; Erdem S; Marandino L; Marchioni M; Muselaers CHJ; Palumbo C; Pavan N; Pecoraro A; Roussel E; Warren H; Pandolfo SD; Chen R; Zhou W; Zhai W; He M; Li Y; Han B; Wan J; Zeng X; Yan J; Fu Y; Ji C; Fan X; Zhang G; Zhao C; Jing T; Wang A; Feng C; Zhao H; Sun D; Wang L; Tai S; Zhang C; Chen S; Liu Y; Xu Z; Wang H; Gao J; Wang F; Cheng J; Miao H; Rao Q; Wang J; Xu N; Wang G; Liang C; Liu Z; Xia D; Jiang J; Zu X; Chen M; Guo H; Qin W; Wang Z; Xue W; Shi B; Zhou X; Wang S; Zheng J; Ge J; Feng X; Li M; Chen C; Qu L; Wang L;
Eur Urol Oncol; 2024 Feb; 7(1):112-121. PubMed ID: 37468393
[TBL] [Abstract] [Full Text] [Related]
3. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
Zhou S; Lu Y; Chen Y; Gan W
Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
[TBL] [Abstract] [Full Text] [Related]
4. Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer.
Taparra K; Qu V; Pollom E
JAMA Netw Open; 2022 Aug; 5(8):e2226327. PubMed ID: 35960520
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of the Surgical Margin Threshold for Avoiding Recurrence after Partial Nephrectomy in Patients with Renal Cell Carcinoma.
Lee J; Kim J; Kim JC; Ham WS; Han WK; Rha KH; Choi YD; Jang WS
Yonsei Med J; 2022 Feb; 63(2):173-178. PubMed ID: 35083903
[TBL] [Abstract] [Full Text] [Related]
6. Leptin Is Associated with Poor Clinical Outcomes and Promotes Clear Cell Renal Cell Carcinoma Progression.
Fan WL; Yeh YM; Liu TT; Lin WM; Yang TY; Lee CW; Lin TC
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33804101
[TBL] [Abstract] [Full Text] [Related]
7. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract] [Full Text] [Related]
8. Black race may be associated with worse overall survival in renal cell carcinoma patients.
Anastos H; Martini A; Waingankar N; Paulucci DJ; Beksac AT; Daza J; Patel HV; Gin GE; Sfakianos JP; Badani KK
Urol Oncol; 2020 Dec; 38(12):938.e9-938.e17. PubMed ID: 32950398
[TBL] [Abstract] [Full Text] [Related]
9. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis.
Ssentongo P; Ssentongo AE; Heilbrunn ES; Ba DM; Chinchilli VM
PLoS One; 2020; 15(8):e0238215. PubMed ID: 32845926
[TBL] [Abstract] [Full Text] [Related]
10. Association of bullous pemphigoid and comorbid health conditions: a case-control study.
Lee S; Rastogi S; Hsu DY; Nardone B; Silverberg JI
Arch Dermatol Res; 2021 Jul; 313(5):327-332. PubMed ID: 32647978
[TBL] [Abstract] [Full Text] [Related]
11. The value of renal score in both determining surgical strategies and predicting complications for renal cell carcinoma: A systematic review and meta-analysis.
Shi N; Zu F; Shan Y; Chen S; Xu B; Du M; Chen M
Cancer Med; 2020 Jun; 9(11):3944-3953. PubMed ID: 32281277
[TBL] [Abstract] [Full Text] [Related]
12. Clear cell sarcoma of the kidney in a 62-year-old patient presenting with generalized pruritus.
Zhang Y; Li J; Wang Y
BMC Cancer; 2019 Nov; 19(1):1034. PubMed ID: 31676003
[TBL] [Abstract] [Full Text] [Related]
13. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
[No Abstract] [Full Text] [Related]
14. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract] [Full Text] [Related]
15. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract] [Full Text] [Related]
16. The correlation between affected renal function and affected renal residual volume: A retrospective outcome of laparoscopic nephron-sparing partial nephrectomy with segmental renal artery blocking-up for localized renal tumors.
Chen FM; Hu RJ; Jiang XN; Zhong SW; Tang S
Medicine (Baltimore); 2019 Jan; 98(2):e13927. PubMed ID: 30633167
[TBL] [Abstract] [Full Text] [Related]
17. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract] [Full Text] [Related]
18. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
Khong B; Lawson BO; Ma J; McGovern C; Van Atta JK; Ray A; Khong HT
BMC Cancer; 2018 Oct; 18(1):1007. PubMed ID: 30342473
[TBL] [Abstract] [Full Text] [Related]
19. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Escudier B; Gerletti P; Li S; Casey M; Laguerre B; Pandha HS; Pantuck AJ; Patel A; Lechuga MJ; Ravaud A
Clin Cancer Res; 2018 Apr; 24(7):1554-1561. PubMed ID: 29374054
[No Abstract] [Full Text] [Related]
20. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival.
Kee KM; Wang JH; Wang CC; Cheng YF; Lu SN
Sci Rep; 2016 Jul; 6():30156. PubMed ID: 27444261
[TBL] [Abstract] [Full Text] [Related]
[Next]
